SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic analysis solutions, today announced that preliminary study data using DNA markers indicates the ability of Sequenom’s SEQureDx™ Technology to determine fetal gender early in pregnancy, which could reduce the need for invasive prenatal procedures in women with fetuses at risk for X-link or sex-dependent genetic disorders. A poster of the study, “Early Fetal Sex Determination Using Cell Free DNA from Maternal Plasma,” was presented by Sequenom scientist Dirk van den Boom, Ph.D., on March 15 at the 2008 American College of Medical Genetics (ACMG) Annual Clinical Genetics Meeting in Phoenix, Ariz.
